RecepTech Inc.'s core technology is to develop products that can be applied to various fields through the technology to mass-produce and purify various receptors in E. coli system and the technology to manufacture them into nanodisc.
The core technology is a technology for producing cancer cell-specific G-protein-coupled receptors in the form of nanodisc, which are the optimal antigens, and a targeted anticancer antibody screening system that resolves nonspecific antibody background through this technology. A domestic patent has been registered and a U.S. application has been filed.

Products using this technology are cancer cell-targeting antibody and small molecule screening system using cancer cell-specific (G-protein-coupled receptor) nanodisc antigen. which can accurately and quickly discover various cancer cell-targeting anticancer antibody and small molecule candidates.